What were the specific cognitive outcome measures (e.g., ADAS‑Cog, CDR‑SB) and their statistical significance?

Based on the press‑release excerpt you shared, Spinogenix announced that the Phase 2a “first‑cohort” of the SPG302 trial showed progress in cognitive outcome measures and a favorable safety profile. However, the brief you provided does not list the specific cognitive instruments that were used (e.g., ADAS‑Cog, CDR‑SB, MMSE, etc.) nor the statistical results (e.g., p‑values, confidence intervals, effect sizes) associated with those measures.

In other words, the details you’re asking for—which exact cognitive scales were evaluated and how statistically significant the observed changes were—are not included in the summary you posted. To obtain that information you would need to consult the full Spinogenix press release, the company’s investor presentation, or any accompanying clinical‑trial data release that contains the complete results. Those sources typically provide a table of endpoints (e.g., change from baseline on ADAS‑Cog, CDR‑SB, or other neuropsychological tests) together with the corresponding statistical metrics (p‑values, confidence intervals, etc.).

If you can locate the complete press release or the detailed trial results, feel free to share those excerpts and I can help interpret the specific outcome measures and their significance. Otherwise, with the current excerpt the requested specifics cannot be provided.